Infliximab therapy for sarcoidosis (lupus pernio)
Identifieur interne : 001F85 ( Main/Exploration ); précédent : 001F84; suivant : 001F86Infliximab therapy for sarcoidosis (lupus pernio)
Auteurs : H. Haley ; W. Cantrell ; K. Smith [États-Unis]Source :
- British Journal of Dermatology [ 0007-0963 ] ; 2004-01.
English descriptors
- Teeft :
- Activator, Arthritis rheum, Bone cysts, British association, British journal, Clinical disease, Corticosteroid, Cutaneous, Cutaneous disease, Cutaneous lesions, Cyst, Cytokine, Cytotoxic, Cytotoxic therapies, Dermatologist, Dermatology, Disease activity, Etanercept, Granuloma, High dose, High levels, Human murine chimeric antibody, Humoral autoimmunity, Immune, Infliximab, Infusion, Insulin resistance, Internal disease, Ligand, Lupus, Lupus pernio, Metformin hydrochloride, Natural inhibitors, Necrosis, Nodule, Nuclear factor, Oral corticosteroids, Pernio, Rankl, Receptor, Receptor activator, Receptor fusion protein, Rheumatoid, Rheumatoid arthritis, Rheumatoid arthritis patients, Sarcoidosis, Sarcoidosis vasc, Second infusion, Severe disease, Soluble receptor activator, Third infusion, Tumor necrosis factor, Tumour, Tumour necrosis.
Abstract
Sarcoidosis is a chronic granulomatous disease of unknown aetiology in which the primary cytokine tumour necrosis factor (TNF)‐α appears to play a major role. Older immune‐modulating drugs including corticosteroids, antimalarials and thalidomide, as well as cytotoxic drugs with immune modulatory effects, have been used to control disease. We present a patient with severe mutilating cutaneous sarcoidosis (lupus pernio) who had showed only partial response to courses of a wide spectrum of immune modulators and cytotoxic therapies, and who had developed significant side‐effects due to prolonged high‐dose corticosteroids. However, the patient's cutaneous disease responded rapidly to the TNF‐α inhibitor infliximab.
Url:
DOI: 10.1111/j.1365-2133.2004.05769.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000431
- to stream Istex, to step Curation: 000431
- to stream Istex, to step Checkpoint: 000E26
- to stream Main, to step Merge: 002000
- to stream Main, to step Curation: 001F85
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Infliximab therapy for sarcoidosis (lupus pernio)</title><author><name sortKey="Haley, H" sort="Haley, H" uniqKey="Haley H" first="H." last="Haley">H. Haley</name></author><author><name sortKey="Cantrell, W" sort="Cantrell, W" uniqKey="Cantrell W" first="W." last="Cantrell">W. Cantrell</name></author><author><name sortKey="Smith, K" sort="Smith, K" uniqKey="Smith K" first="K." last="Smith">K. Smith</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7EE58DE01EA84FFEC222AE949C403657E0B376C1</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1111/j.1365-2133.2004.05769.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-5PSLT2KJ-T/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000431</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000431</idno><idno type="wicri:Area/Istex/Curation">000431</idno><idno type="wicri:Area/Istex/Checkpoint">000E26</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000E26</idno><idno type="wicri:doubleKey">0007-0963:2004:Haley H:infliximab:therapy:for</idno><idno type="wicri:Area/Main/Merge">002000</idno><idno type="wicri:Area/Main/Curation">001F85</idno><idno type="wicri:Area/Main/Exploration">001F85</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Infliximab therapy for sarcoidosis (lupus pernio)</title><author><name sortKey="Haley, H" sort="Haley, H" uniqKey="Haley H" first="H." last="Haley">H. Haley</name><affiliation><wicri:noCountry code="no comma">Departments of Dermatology</wicri:noCountry></affiliation></author><author><name sortKey="Cantrell, W" sort="Cantrell, W" uniqKey="Cantrell W" first="W." last="Cantrell">W. Cantrell</name><affiliation><wicri:noCountry code="no comma">Departments of Dermatology</wicri:noCountry></affiliation></author><author><name sortKey="Smith, K" sort="Smith, K" uniqKey="Smith K" first="K." last="Smith">K. Smith</name><affiliation></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pathology, University of Alabama at Birmingham, Birmingham, AL</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">British Journal of Dermatology</title><title level="j" type="alt">BRITISH JOURNAL OF DERMATOLOGY</title><idno type="ISSN">0007-0963</idno><idno type="eISSN">1365-2133</idno><imprint><biblScope unit="vol">150</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="146">146</biblScope><biblScope unit="page" to="149">149</biblScope><biblScope unit="page-count">4</biblScope><publisher>Blackwell Science Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2004-01">2004-01</date></imprint><idno type="ISSN">0007-0963</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0007-0963</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Activator</term><term>Arthritis rheum</term><term>Bone cysts</term><term>British association</term><term>British journal</term><term>Clinical disease</term><term>Corticosteroid</term><term>Cutaneous</term><term>Cutaneous disease</term><term>Cutaneous lesions</term><term>Cyst</term><term>Cytokine</term><term>Cytotoxic</term><term>Cytotoxic therapies</term><term>Dermatologist</term><term>Dermatology</term><term>Disease activity</term><term>Etanercept</term><term>Granuloma</term><term>High dose</term><term>High levels</term><term>Human murine chimeric antibody</term><term>Humoral autoimmunity</term><term>Immune</term><term>Infliximab</term><term>Infusion</term><term>Insulin resistance</term><term>Internal disease</term><term>Ligand</term><term>Lupus</term><term>Lupus pernio</term><term>Metformin hydrochloride</term><term>Natural inhibitors</term><term>Necrosis</term><term>Nodule</term><term>Nuclear factor</term><term>Oral corticosteroids</term><term>Pernio</term><term>Rankl</term><term>Receptor</term><term>Receptor activator</term><term>Receptor fusion protein</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatoid arthritis patients</term><term>Sarcoidosis</term><term>Sarcoidosis vasc</term><term>Second infusion</term><term>Severe disease</term><term>Soluble receptor activator</term><term>Third infusion</term><term>Tumor necrosis factor</term><term>Tumour</term><term>Tumour necrosis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Sarcoidosis is a chronic granulomatous disease of unknown aetiology in which the primary cytokine tumour necrosis factor (TNF)‐α appears to play a major role. Older immune‐modulating drugs including corticosteroids, antimalarials and thalidomide, as well as cytotoxic drugs with immune modulatory effects, have been used to control disease. We present a patient with severe mutilating cutaneous sarcoidosis (lupus pernio) who had showed only partial response to courses of a wide spectrum of immune modulators and cytotoxic therapies, and who had developed significant side‐effects due to prolonged high‐dose corticosteroids. However, the patient's cutaneous disease responded rapidly to the TNF‐α inhibitor infliximab.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Alabama</li></region></list><tree><noCountry><name sortKey="Cantrell, W" sort="Cantrell, W" uniqKey="Cantrell W" first="W." last="Cantrell">W. Cantrell</name><name sortKey="Haley, H" sort="Haley, H" uniqKey="Haley H" first="H." last="Haley">H. Haley</name></noCountry><country name="États-Unis"><region name="Alabama"><name sortKey="Smith, K" sort="Smith, K" uniqKey="Smith K" first="K." last="Smith">K. Smith</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F85 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001F85 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:7EE58DE01EA84FFEC222AE949C403657E0B376C1
|texte= Infliximab therapy for sarcoidosis (lupus pernio)
}}
| This area was generated with Dilib version V0.6.33. |  |